Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Details 詳細情報について

• CRID

  1361699996151963136

• DOI

  10.1016/j.jaad.2015.03.049

• ISSN

  01909622

• Web Site

  https://api.elsevier.com/content/article/PII:S0190962215014942?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0190962215014942?httpAccept=text/plain

• Data Source

  • Crossref